Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4629 - OHERA – A Real World Study of Cardiac Events in >3700 Patients with HER2-positive Early Breast Cancer Treated with Trastuzumab: Final Analysis


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Supportive Care and Symptom Management;  Breast Cancer


Elisabeth Lidbrink


Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362


E. Lidbrink1, J. Erfan2, E. Chmielowska3, B. Otremba4, A. Bouhlel5, S. Lauer6, M. Liste Hermoso5, E. Nüesch6, M. Shing7, V. Misra8

Author affiliations

  • 1 Karolinska Institute, Karolinska University Hospital, SE-171 77 - Stockholm/SE
  • 2 Josa Andras, Teaching Hospital, Nyiregyhaza/HU
  • 3 Regionalne Centrum Onkologii, Bydgoszcz, Poland and Medical University Nicolaus Copernicus, Torun/PL
  • 4 Onkologische Praxis, Oldenburg, Oldenburg/DE
  • 5 Global Pharma Development, F Hoffmann-La Roche Ltd, Basel/CH
  • 6 Biostatistics, F Hoffmann-La Roche Ltd, Basel/CH
  • 7 Genentech Inc, Clovis Oncology Inc, San Francisco/US
  • 8 The Christie Clinic, The Christie NHS Foundation Trust, Manchester/GB


Abstract 4629


As of Sept 2016, > 2.2 million breast cancer (BC) patients (pts) have received trastuzumab (Herceptin®; H) in clinical trial or real world settings. Risk of cardiac failure in pts treated with H in real world practice may differ from that observed in a clinical trial setting.


OHERA (NCT01152606) is a non-interventional post-approval safety study that investigated incidence of symptomatic congestive heart failure (CHF) and cardiac death in pts with HER2-positive early BC (EBC) receiving adjuvant intravenous H (H IV) in routine clinical practice, per the EU Summary of Product Characteristics (SmPC). Pts with HER2-positive EBC (stage I–IIIb) considered for treatment with H IV per the EU SmPC were enrolled, treated and monitored per local practice. Primary endpoints were incidence of symptomatic CHF (New York Heart Association [NYHA] class II–IV) and incidence of cardiac death. Secondary endpoints included time to onset of CHF. The final analysis included pt data collected for up to 5 years or until death, loss to follow-up or consent withdrawal.


Pts were enrolled Aug 2007–Nov 2010 at 199 sites across 9 countries. The safety population included 3733 pts with EBC treated with H IV. Median treatment duration was 11.8 months; median follow-up was 60.1 months. Incidence of symptomatic CHF was 2.8% (n = 106); including severe symptomatic CHF (NYHA class III–IV) in 1.0% (n = 38) pts. Median time to onset of symptomatic CHF was 5.7 months (95% CI 5.3–6.5) and 77 (72.6%) pts achieved CHF resolution. Incidence of cardiac death was 0.2% (n = 6). 251 pts had a left ventricular ejection fraction (LVEF) drop of ≥ 10% from baseline to 


OHERA is the largest study investigating the cardiac safety of adjuvant H IV in a real world setting to date. Final analysis results were consistent with cardiac safety results from previous adjuvant H IV clinical trials in EBC, and the baseline risk factors for CHF reported in the H IV EU SmPC.

Clinical trial identification

Protocol number: BO20652/RO 45-2317 ClinicalTrials.gov NCT01152606

Legal entity responsible for the study

F Hoffmann-La Roche Ltd


F. Hoffmann-La Roche Ltd., Basel, Switzerland


A. Bouhlel, M. Liste Hermoso: Employee of F Hoffmann-La Roche Ltd. S. Lauer: Contract work for Hoffmann-La Roche Ltd. E. Nüesch: Stock ownership: Roche. Employee of F. Hoffmann-La Roche Ltd. M. Shing: Previous employee of Genentech Inc. & current collaboration with Genentech Inc. V. Misra: Membership of an advisory board: Amgen, Eisai, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.